[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental group: 25 patients with SARS associated with SARS-CoV-2 will receive standard treatment according to the current care protocol (SOC); in addition to an application of Secuquinumab (dose of 300mg) subcutaneously on day 0 (D0 - day of inclusion in the study) and another on the 7th (D7 - 7 days later); if the inclusion and exclusion criteria remain applicable.Control group: 25 patients with SARS associated with SARS-CoV-2 will receive only standard treatment according to the current care protocol (SOC).;Drug;D12.776.124.486.485.114.224", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1177, "treatment_name": "Secukinumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental group: 25 patients with SARS associated with SARS-CoV-2 will receive standard treatment according to the current care protocol (SOC); in addition to an application of Secuquinumab (dose of 300mg) subcutaneously on day 0 (D0 - day of inclusion in the study) and another on the 7th (D7 - 7 days later); if the inclusion and exclusion criteria remain applicable.Control group: 25 patients with SARS associated with SARS-CoV-2 will receive only standard treatment according to the current care protocol (SOC).;Drug;Antibodies; Monoclonal", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]